Navigation Links
China Health Resource Signs Two New Agreements for the Sale of Gastrodia Valued at $10 Million USD (Corrected*)
Date:1/26/2012

SICHUAN, China, Jan. 26, 2012 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: CHRI.OB News), announced today that it has signed two new agreements for the sale of Gastrodia valued at 67.5 Million RMB or approximately $10.7 Million USD (Corrected*).  The agreements are with Chongqing Valley Pharm Corp and Sichuan Zhiyuanguanghe Pharm Corp and provide for a combined purchase total of 550 tons of Gastrodia from January 1, 2012 to December 31, 2012.

CHRI recently signed a 3 year exclusive agreement with a leading producer of Gastrodia in Pingwu, Sichuan. The quality of Gastrodia under this supply agreement is expected to meet the latest formal TCM pharmaceutical standard and gives CHRI continued leverage in the Traditional Chinese Medicine (TCM) marketplace in China, as the main controlling distributor and supplier of pharmaceutical grade Gastrodia (also known as Tianma).

"Demand is high for pharmaceutical grade Gastrodia and the company expects both our Gastrodia product revenues and bottom line will surpass last year.  We have started the new year with strong demand aided by our brand recognition and high quality GAP standards," stated Jiayin Wang, Chairman and CEO of CHRI.

Gastrodia is recognized as one of the higher value herbs in TCM.

"We have announced continuous record growth for 2011 and anticipate continued double-digit growth for Gastrodia product line in 2012.  We anticipate another record breaking year in our revenues and profits," says Weihai Liu, CFO of CHRI.

"In addition to great opportunities for Gastrodia, Dahurian Angelica (DAR) is successfully established as a franchise.   With our Dragonhead Enterprise status, which confirms CHRI as a quality-oriented government sanctioned enterprise, we are positioned  for a large scale global market penetration for CHRI's products," says Jiayin Wang.

(*) "An earlier version of this release erroneously reported the revenue from the agreements as $1.7 million US Dollars instead of $10.7 Million US Dollars and 67.5 RMB instead of 67.5 Million RMB."

About CHRI

China Health Resource, Inc. engages in the development, manufacturing, processing, marketing and sale of raw and pharmaceutical TCM products including Dahurian Angelica Root (DAR) and Rhizoma Gastrodiae and is only the provider of GAP quality DAR in the People's Republic of China under the registered Trademark Chuan Baizhi™. DAR, which is also known as "Bai Zhi" in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The Company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The Company was founded in 2001 and is based in Suining, Sichuan Province.

For more information, please visit http://chinahealthresource.com.

Certain statements in this document regarding financial matters, other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Since these statements involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.


'/>"/>
SOURCE China Health Resource, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. China Health Resource Signs 3 Year Exclusive Agreement for Acquisition of Gastrodia Extending Very Successful Product Line Through 2015
2. China Health Resource Pharmaceutical Grade Gastrodia Product Line Expected to Contribute $8 Million in Revenue to 2011 Year End
3. BioChina International 2012
4. China Pharmaceutical Equipment Industry Report, 2011-2012
5. China Kanghui Holdings Renews High and New Technology Enterprises Status of Its PRC Operating Subsidiaries
6. Airway and Anesthesia Devices Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
7. China Health Resource CEO Delivers Speech at 10th Year Anniversary Celebration
8. Magnetic Resonance Imaging (MRI) Systems Market Outlook in BRICS (Brazil, Russia, India, China, South Africa) to 2017
9. China Kanghui Holdings Receives FDA Approvals for Hip and Knee Systems
10. China Kanghui Holdings to Present at the 30th Annual J.P. Morgan Healthcare Conference
11. Vivo Ventures Closes $375 Million 7th Fund to Invest in Healthcare in the U.S. and Greater China
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/24/2017)... FinancialBuzz.com News Commentary   ... Medical cannabis products around the world are projected to gain popularity. A ... market will reach a value of USD 55.8 billion by 2025. ... growing industry. By the end of 2016, 28 states have now laws ... conservative states like Arkansas and North ...
(Date:3/24/2017)... -- Global Ampoules Market report provides a ... and industry chain structure. The Ampoules market analysis is ... landscape analysis, and major regions, development status. ... Complete ... 10 company profiles and 183 tables and figures is ...
(Date:3/24/2017)... , March 24, 2017  Eli Lilly and ... plans to invest $850 million in its U.S. ... across its U.S. enterprise, including research laboratories, manufacturing ... are being driven by demand for Lilly products, ... medicines in development targeting cancer, pain, diabetes and ...
Breaking Medicine Technology:
(Date:3/25/2017)... , ... March 25, 2017 , ... Getting earned media ... public relations partner. , All through the year, Garden Media aims to provide ... working with key influencers and pitching client’s key messages to gain coveted ...
(Date:3/24/2017)... ... March 24, 2017 , ... Infectious disease ... hospitals in the United States, it’s a threat that is constantly changing and ... infection prevention and offers strategies for the healthcare community to help decrease the ...
(Date:3/24/2017)... (PRWEB) , ... March 24, 2017 , ... The iaedp ... and other medical professionals caring for those suffering from the full spectrum of disordered ... 800, as eating disorders professionals from nearly all 50 states and several countries converged ...
(Date:3/24/2017)... ... 24, 2017 , ... Northridge dentists, Dr. Michel ... sleep apnea and TMJ at their office. TMJ, or temporomandibular joint disorder, has ... type, is increasingly being treated at dental offices with newly developed procedures and ...
(Date:3/24/2017)... ... March 24, 2017 , ... ... of enhancements, upgrading their training and leads programs. , In February, 2017, Empower ... elite sales agents, Performance Partners is designed to teach how to maximize their ...
Breaking Medicine News(10 mins):